Hasil Pencarian  ::  Simpan CSV :: Kembali

"AbstrakVenous thromboembolism (VTE) is a fatal yet potentially preventable complication of surgery. Routine thromboprophylaxis is still unequivocal prescription is problematic due to perception of low VTE incidence among Asian population. This study aims to investigate the incidence of VTE and thromboprophylaxis prescription among patients undergoing major surgery in a Singapore hospital.Methods: This was a cross-sectional study. Data were obtained from medical record of 1,103 patients who had underwent major orthopaedic or abdominal surgery in 2011-2012 at Khoo Teck Puat Hospital, Singapore. Incidence of VTE events either in the same admission or re-admission in less than one month time were noted as study parameters.Results: Incidence of VTE was 2.1% (95% CI: 1.67 - 2.53) of which 1.3% and 0.8% were DVT and PE cases respectively. Age, gender, history of VTE, ischemic heart disease, and mechanical prophylaxis were associated with VTE incidence based on bivariate analysis. The prescription of pharmacological thromboprophylaxis was associated with prior anticoagulant medication, type of surgery, and incidence of new bleeding.Conclusion: Subsequent to major surgeries, VTE is as common in Asian patients as published data in other populations. Pharmacologic thromboprophylaxis should be considered as recommended in non-Asian guidelines."

"Kanker telah diketahui sebagai faktor risiko kuat penyebab tromboemboli, baik emboli paru maupun trombosis vena dalam. Emboli paru sendiri seringkali tidak bergejala padahal angka mortalitas bisa mencapai 80%. Tipe histopatologi adenokarsinoma merupakan salah satu faktor risiko yang meningkatkan kejadian emboli paru. Penelitian ini bertujuan untuk mengetahui proporsi kejadian emboli paru dan trombosis vena pada kelompok kemungkinan tinggi menurut skor Revisi Geneva dan memperoleh besar kemungkinan kejadian emboli paru (EP) serta hubungannya dengan tipe histopatologi kanker padat. Penelitian menggunakan potong lintang dan didapatkan 124 subjek diikutkan dalam penelitian ini yang terdiri atas kelompok adenokarsinoma dan non adenokarsinoma masing-masing sebesar 62 subjek. Berdasarkan skor Revisi Geneva, sebanyak 11 (8,8%) subjek termasuk ke dalam kelompok kemungkinan rendah, 96 (77,4%) subjek termasuk ke dalam kelompok kemungkinan menengah dan 17 (13,8%) subjek ke dalam kelompok kemungkinan tinggi. Kejadian tromboemboli vena pada kelompok kemungkinan tinggi mencapai 94,1% dengan 58,8% mengalami emboli paru dan trombosis vena dalam secara bersamaan, 11,8% hanya mengalami emboli paru saja dan 23,6% mengalami thrombosis vena dalam saja. Tipe histopatologi adenokarsinoma memiliki risiko 2,58 kali lebih tinggi untuk masuk kedalam kelompok kemungkinan kejadian tinggi emboli paru menurut skor Revisi Geneva bila dibandingkan pada subjek dengan tipe histopatologi non adenokarsinoma. Sebagai kesimpulan, kanker padat dengan tipe histopatologi adenokarsinoma meningkatkan kemungkinan kejadian emboli paru bila dibandingkan dengan tipe non adenokarsinoma.

---

Cancer is widely known as a strong risk factor of thromboembolism, which consist of two kind are pulmonary embolism and deep vein thrombosis. We mainly focused on pulmonary embolism in this research. Pulmonary embolism is often asymptomatic which the mortality rate can reach 80%. Adenocarcinoma histopathological type has been proved as one of the risk factors that increase the occurance of pulmonary embolism. This research determine the proportion of pulmonary embolism and deep vein thrombosis events in high clinical probability group based on Revised Geneva score and the correlation with solid tumor histopathological type. This research used cross sectional method with 124 subjects participated in this research which consisted of 62 patients for each of adenocarcinoma and non-adeocarcinoma group. Mean of patient age was 52 years old and the sum of female participant was larger than male. Based on Revised Geneva score, 11 (8,8%) participants were in low risk clinical probability group, 96 (77,4%) participant were in middle risk clinical probability group and the rest of 17 (13,8%) participants were in high risk clinical probability group. The total event of vena thromboembolism in high risk clinical probability group reached 94,1% whereas 58,8% got both pulmonary embolism and deep vein thrombosis simultaneously, 11,8% with pulmonary embolism alone and 23,6% with vein deep vein thrombosis alone. Subjects with histopathological type of AC were 2.58 times greater to be a high-probability group of the Revised Geneva Score compared with NAC. As the conclusion, Solid cancer with histopathological type of AC increases the likelihood of PE incidence when compared with NAC."

"Latar belakang. Risiko Venous Thromboembolism (VTE) yang terkait dengan keganasan adalah 4,1 kali lipat lebih besar dibandingkan dengan pasien tanpa keganasan. Pasien keganasan memiliki risiko perdarahan yang lebih besar dengan terapi antikoagulan yang umum digunakan. Inferior Vena Cava Filter (IVCF) telah direkomendasikan sebagai alternatif yang kontroversial.Tujuan. Untuk menemukan bukti ilmiah tertinggi dalam keamanan, manfaat, dan dampak klinis IVCF untuk mengelola VTE terkait keganasan.Metode. Sesuai dengan pedoman PRISMA, pada situs berbasis data Cochrane, PubMed, dan ClinicalKey dicari menggunakan kata kunci ("Inferior Vena Cava Filter" or "IVCF") and (“Anticoagulant”) and ("Cancer" or "Malignancy") and ("Venous Thromboembolism" or "VTE" or "Pulmonary Embolism" or "Deep Vein Thrombosis") and ("Safety" or "Benefit" or "Complication" or "Recurrence" or "Survival Rate" or "Mortality"). Artikel-artikel ini ditinjau dan dinilai.Hasil. Ada 10 artikel yang ditinjau (1.191 partisipan). Komplikasi IVCF yang ditemukan: migrasi filter (0,9%), trombosis vena cava (3,7%), PE berulang (2,8%); fraktur filter (0,9%); dan penetrasi IVCF (0,9%). Tidak ada kematian yang ditemukan pada pasien karena komplikasi karena penyisipan filter (LOE 2). Penyisipan IVCF dapat mengurangi tingkat PE tetapi dengan peningkatan jumlah DVT (DVT: dengan filter vs tanpa filter: 35,7% vs 27,5%; HR 1,52; CI95 % 1,02–2,27; p = 0,042; PE: 6,2% vs. 15,1 %; HR 0,37; 95% CI 0,17–0,79; p = 0,008). Enam studi tidak menemukan peningkatan yang signifikan secara statistik dalam mortalitas terkait PE.Kesimpulan. IVCF aman dan bermanfaat untuk pengelolaan VTE terkait keganasan, terutama pada pasien dengan kontraindikasi antikoagulan (LOE 2, 3 dan 4).

---

Background. The risk of venous thromboembolism (VTE) associated with malignancy is 4.1-fold greater compared to patients without malignancy. Malignancy patient have greater risk of bleeding with the commonly used anticoagulant therapy. Inferior Vena Cava Filter (IVCF) have been recommended as an controversial alternative.

Objective. To find the highest evidence in the safety, benefit, and clinical outcome of the IVCF for managing VTE associated with malignancy.

Method. Aligning with PRISMA guidelines, online databases Cochrane, PubMed, ScienceDirect and ClinicalKey were searched using keywords ("Inferior Vena Cava Filter" or "IVCF") and (“Anticoagulant”) and ("Cancer" or "Malignancy") and ("Venous Thromboembolism" or "VTE" or "Pulmonary Embolism" or "Deep Vein Thrombosis") and ("Safety" or "Benefit" or "Complication" or "Recurrence" or "Survival Rate" or "Mortality"). These articles were reviewed and appraised.

Results. There were 10 articles reviewed (1,191 participants). Complication of IVCF found: filter migration (0.9%), vena cava thrombosis (3.7%), recurrent PE (2.8%); filter fracture (0.9%); and IVCF penetration (0.9%). No mortality was found in patients due to complications due to filter insertion (LOE 2). IVCF insertion can reduce PE rates but with an increase in the number of DVT (DVT: with filter vs without filters: 35.7% vs 27.5%; HR 1.52; CI95 % 1.02–2.27; p = 0.042 ; PE: 6.2% vs. 15.1%; HR 0.37; 95% CI 0.17–0.79; p = 0.008). Six studies found no statistically significant increase in PE-related mortality.

Conclusion. IVCF is safe and beneficial for the management of malignancy-associated VTE, especially in patients with contraindications to anticoagulants (LOE 2, 3 and 4)."